ReviewArquivos brasileiros de cardiologia2016
Cardiac Regeneration using Growth Factors: Advances and Challenges.
Review in Arquivos brasileiros de cardiologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Review
- Electrically conductive biopolymer-based hydrogels and fibrous materials fabricated using 3D printing and electrospinning for cardiac tissue engineering.Bioactive materials · 2025Review
- The Role of the Extracellular Matrix in Inducing Cardiac Cell Regeneration and Differentiation.Cells · 2025Review
- An overview on cardiac regeneration revolution: exploring the promise of stem cell therapies.Molecular biology reports · 2025Review
- Customized Heparinized Alginate and Collagen Hydrogels for Tunable, Local Delivery of Angiogenic Proteins.ACS biomaterials science & engineering · 2025Article
- Dynamic map illuminates Hippo-cMyc module crosstalk driving cardiomyocyte proliferation.Development (Cambridge, England) · 2025Article
- Review
- Mitigation of Fibrosis after Myocardial Infarction in Rats by Using a Porcine Cholecyst Extracellular Matrix.Comparative medicine · 2023Article
- Cell-Free Treatments: A New Generation of Targeted Therapies for Treatment of Ischemic Heart Disease.Cell journal · 2022Article
- Hyaluronan and elastin-like protein (HELP) gels significantly improve microsphere retention in the myocardium.Biomaterials science · 2022Article
- Progress in Bioengineering Strategies for Heart Regenerative Medicine.International journal of molecular sciences · 2022Review
- Oxygen Delivery Approaches to Augment Cell Survival After Myocardial Infarction: Progress and Challenges.Cardiovascular toxicology · 2022Review
- Injectable selenium-containing polymeric hydrogel formulation for effective treatment of myocardial infarction.Frontiers in bioengineering and biotechnology · 2022Article
- Neuregulin-1, a potential therapeutic target for cardiac repair.Frontiers in pharmacology · 2022Review
- Vibrational Spectroscopy-Based Chemometrics Analysis ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Comprehending Cardiac Dysfunction by Oxidative Stress: Untargeted Metabolomics ofFrontiers in chemistry · 2022Article
- What Is the Status of Regenerative Therapy in Heart Failure?Current cardiology reports · 2021Review
- Myocardial protection by heparin-based coacervate of FGF10.Bioactive materials · 2021Article
- Synthesis and characterization of peptide conjugated human serum albumin nanoparticles for targeted cardiac uptake and drug delivery.PloS one · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction is the most significant manifestation of ischemic heart disease and is associated with high morbidity and mortality. Novel strategies targeting at regenerating the injured myocardium have been investigated, including gene therapy, cell therapy, and the use of growth factors. Growth factor therapy has aroused interest in cardiovascular medicine because of the regeneration mechanisms induced by these biomolecules, including angiogenesis, extracellular matrix remodeling, cardiomyocyte proliferation, stem-cell recruitment, and others. Together, these mechanisms promote myocardial repair and improvement of the cardiac function. This review aims to address the strategic role of growth factor therapy in cardiac regeneration, considering its innovative and multifactorial character in myocardial repair after ischemic injury. Different issues will be discussed, with emphasis on the regeneration mechanisms as a potential therapeutic resource mediated by growth factors, and the challenges to make these proteins therapeutically viable in the field of cardiology and regenerative medicine. Resumo O infarto do miocárdio representa a manifestação mais significativa da cardiopatia isquêmica e está associado a elevada morbimortalidade. Novas estratégias vêm sendo investigadas com o intuito de regenerar o miocárdio lesionado, incluindo a terapia gênica, a terapia celular e a utilização de fatores de crescimento. A terapia com fatores de crescimento despertou interesse em medicina cardiovascular, devido aos mecanismos de regeneração induzidos por essas biomoléculas, incluindo angiogênese, remodelamento da matriz extracelular, proliferação de cardiomiócitos e recrutamento de células-tronco, dentre outros. Em conjunto, tais mecanismos promovem a reparação do miocárdio e a melhora da função cardíaca. Esta revisão pretende abordar o papel estratégico da terapia, com fatores de crescimento, para a regeneração cardíaca, considerando seu caráter inovador e multifatorial sobre o reparo do miocárdio após dano isquêmico. Diferentes questões serão discutidas, destacando-se os mecanismos de regeneração como recurso terapêutico potencial mediado por fatores de crescimento e os desafios para tornar essas proteínas terapeuticamente viáveis no âmbito da cardiologia e da medicina regenerativa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.